Home / Comparisons / Modafinil vs Adderall

Modafinil vs Adderall

This page is a reference summary of published evidence and regulatory documents. It is not a substitute for individual medical advice, and it is not a recommendation to take or avoid any medicine.

Medically reviewed by Dr. Sofia Lindqvist, · Last reviewed 11 August 2026

Modafinil and Adderall are different classes of drug approved for different purposes: modafinil is a wake-promoting agent approved for narcolepsy, OSA-related sleepiness, and shift work disorder, while Adderall is a mixed amphetamine salt approved for ADHD and narcolepsy. For ADHD specifically, the evidence favours amphetamine products; modafinil is not FDA-approved for that indication in adults or children.

They also sit in different DEA schedules, which reflects a real difference in measured abuse liability, not just regulatory history.

On this page

Comparison table

Modafinil Adderall
DEA schedule (US) Schedule IV Schedule II
Core mechanism DAT inhibition (wake-promoting agent) Monoamine releasing agent (reverses DAT/NET/VMAT2)
FDA-approved for ADHD No Yes, ages 3+ (IR) and 6+ (XR)
FDA-approved for narcolepsy Yes Yes
Typical adult dose 200mg once daily 5-40mg/day in divided doses (IR)
Half-life ~15 hours ~10-13 hours (mixed amphetamine salts)

Mechanism difference

Modafinil inhibits the dopamine transporter without triggering transporter-mediated dopamine release, producing a comparatively modest rise in extracellular dopamine relative to classical stimulants. Amphetamine, the active component of Adderall, enters neurons through the dopamine and norepinephrine transporters and reverses their direction, actively releasing dopamine and norepinephrine into the synapse and also affecting vesicular storage via VMAT2. This releasing action is the pharmacological reason amphetamine produces larger increases in synaptic catecholamines, and larger downstream cardiovascular effects, than modafinil at clinically used doses.

Where they differ

For ADHD, the trial evidence clearly favours amphetamine products. Meta-analyses of ADHD pharmacotherapy consistently rank amphetamines among the most effective agents by effect size, while modafinil trials in ADHD have produced smaller and less consistent effects, and the FDA has not approved it for this indication in either adults or children.

Abuse liability differs by an order that shows up directly in scheduling: Adderall is Schedule II, the same tier as cocaine and oxycodone in terms of regulatory control, reflecting documented high abuse and dependence potential. Modafinil is Schedule IV, reflecting lower but non-zero recorded abuse potential in controlled studies.

Cardiovascular effect sizes also differ. Amphetamine products produce larger average increases in heart rate and blood pressure than modafinil at standard therapeutic doses, which is why amphetamine labeling carries a more prominent cardiovascular warning burden.

Where they are the same

Both drugs are approved for narcolepsy, both are Schedule III-or-higher controlled substances in the US, and both carry contraindications around uncontrolled hypertension and significant cardiac disease.

Insomnia, headache, and decreased appetite appear as common side effects for both drugs, though at different relative frequencies. Neither should be combined with monoamine oxidase inhibitors, and both require caution in patients with a history of psychosis, given reports of drug-induced psychiatric symptoms with each.

Who each tends to suit

Adderall is the standard first-line stimulant choice for diagnosed ADHD given the depth of trial evidence. Modafinil tends to be reserved for patients with a diagnosed sleep disorder, or considered off-label where amphetamine stimulants are contraindicated or poorly tolerated, recognising that this off-label use for ADHD rests on weaker evidence than an on-label amphetamine trial.

Frequently asked questions

Is modafinil approved for ADHD?

No. Modafinil is not FDA-approved for ADHD in adults or children. Adderall is approved for ADHD in both. Some clinicians prescribe modafinil off-label for ADHD, but the trial evidence supporting that use is smaller and less consistent than for stimulants.

Which has more abuse potential?

Adderall, a Schedule II controlled substance, has substantially higher recorded abuse and diversion rates than modafinil, a Schedule IV substance. This distinction is reflected directly in their DEA scheduling.

Which raises heart rate and blood pressure more?

Amphetamine products like Adderall produce larger average increases in heart rate and blood pressure than modafinil in comparable dosing, consistent with amphetamine’s direct catecholamine-releasing action versus modafinil’s more selective transporter effect.

Can they be taken together?

This combination is not well studied and should only be considered under specialist supervision, since both affect cardiovascular parameters and sleep, and modafinil’s CYP interactions can alter levels of other co-administered drugs.

Continue reading

References